SOURCE: AmStem Corporation

 AmStem Corporation

July 14, 2010 09:00 ET

AmStem Reports Positive Early Results From SteMixx™ Consumer Study

Consumer Testers Cite Fading Sunspots, Reduced Redness, Softer, Tighter Skin

SAN FRANCISCO, CA--(Marketwire - July 14, 2010) -  AmStem Corporation (OTCBB: AMST), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced today positive early results from its preliminary consumer study of SteMixx™.

David Stark, President of AmStem International, Inc. said, "During the first few days, we asked participants of our initial consumer study of SteMixx™ for their initial impressions. We were not surprised but certainly pleased at how positively they responded." 

Full study results will be available at the end of this month, but participants have already been calling the AmStem International office in San Francisco, with comments such as, "Where can I buy this? This is amazing!" and "I have had good results after just one application." Over 64% of responding participants have made positive comments. The rest said it was too early to tell.

Samples of comments made by participants (reprinted by permission):

  • "Much tighter feeling and less puffy after just two uses"
  • "Less redness in broken capillaries, better circulation in skin, not as much eye puffiness"
  • "Keeps the skin moist. Feels a bit tighter."
  • "Sun spots fading"
  • "Less hyper pigmentation"
  • "Skin softer and complexion more even"
  • "Clearer skin, seems less puffy"

One participant added, "So many manufacturers take advantage of people with false claims. Thank you for using real ingredients that our own bodies notice as their own."

Twenty-one women are participating in the SteMixx™ consumer study across the country. The study asks its participants to refrain from using any other facial skin care products for one month (except for cleanser and sunscreen). Those with any type of recent facial procedure, such as a light or deep peel, dermabrasions or injections were excluded.

Based on these early positive results, AmStem has engaged a labeling consultant for their flagship SteMixx™ product to make it available for retail consumer use as soon as possible in the U.S.

In a related development, AmStem has finalized its submission to an independent Institutional Review Board (IRB) to begin the first clinical trial of SteMixx in the United States. 

Stark said, "This study will provide information to help decide what claims we will make in our labeling and advertising of SteMixx™. The principal investigator will be Dr. Shelly Friedman of the Scottsdale Institute for Cosmetic Dermatology. The study is expected to begin enrollment immediately after IRB approval."

About SteMixx™
SteMixx™, along with an extensive line of cosmeceutical and hair restoration products, was developed by Dr. Han Hoon, CEO of Histostem, Ltd., in Seoul, Korea. Histostem operates one of the largest cord blood banks in the world with over 80,000 units stored for personal and unrelated transplant uses.

SteMixx™ has been approved by the Korean FDA as a "functional cream" for the treatment of facial skin disfiguration associated with signs of aging such as wrinkles. AmStem's professional studies are for the purpose of validating these claims, which have not yet been reviewed by the U.S. FDA.

About AmStem Inc.
AmStem Inc. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the company for use in unrelated transplant for personal storage and use in the family setting for transplant and regenerative medicine. The company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.

An investment profile on AmStem may be found at To receive future releases in e-mail alerts, sign up at

For more information contact AmStem CFO Andrew Norstrud at (813) 283-2556 or Tom Fox at Hawk Associates at (305) 451-1888 or visit:

Forward-Looking Statements
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For these statements, we claim the protection of the safe harbor for forward-looking statement contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capability or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in the press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statement to reflect events or circumstances that occur after the date hereof.

Contact Information

  • Contacts:
    Andrew Norstrud
    AmStem CFO
    (813) 283-2556

    Tom Fox
    Hawk Associates
    (305) 451-1888